Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14127788 | 0.98 | CHRM3 (0.46) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21464455 | 0.82 | MAPT (0.61) | CYP1A2SMN1; SMN2CRHBPCRHR2CYP2D6 | |
| SCHEMBL6402539 | 0.78 | SMN1; SMN2 (0.50) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1042655 | 0.78 | CYP1A2 (0.46) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4116293 | 0.77 | CYP1A2 (0.48) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3236763 | 0.77 | CYP1A2 (0.48) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL6403646 | 0.76 | SMN1; SMN2 (0.49) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2771547 | 0.76 | CASP1 (0.59) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2771738 | 0.75 | CYP1A2 (0.47) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3413188 | 0.74 | KMT2A (0.53) | CHRM3PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| JP-1226819-A | — | — | None | — | — | JP | disclosed |
| EP-3160464-B1 | 6-HYDROXYBUSPIRONE FOR USE IN THE TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2018-07-18 | — | — | EP | disclosed |
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| JP-H01226819-A | MELANCONIA DEPRESSANT AND ITS PRODUCTION | ASTA PHARMA AG | 1989-09-11 | — | — | JP | disclosed |
| EP-0330826-A2 | Use of pyridin-2-ethers or pyridin-2-thioethers with a nitrogen-containing cycloaliphatic ring as agents with an antidepressant activity | ASTA Pharma Aktiengesellschaft (DE) | 1989-09-06 | — | — | EP | disclosed |
| EP-0149088-B1 | PYRIDINE-2-ETHERS RESPECTIVELY PYRIDINE-2-THIOETHERS WITH A NITROGEN CONTAINING CYCLOALIPHATIC RING AND SULFOXIDES,SULFANES AND PYRIDIN-N-OXIDES THEREOF | ASTA Pharma Aktiengesellschaft (DE) | 1989-01-18 | — | — | EP | disclosed |
| US-4643995-A | Analgesic pyridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-02-17 | — | — | US | disclosed |
| EP-0149088-A1 | Pyridine-2-ethers respectively pyridine-2-thioethers with a nitrogen containing cycloaliphatic ring and sulfoxides,sulfanes and pyridin-N-oxides thereof | ASTA Pharma Aktiengesellschaft (DE) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | CHRM3 847/4885PDE4A 419/4885PDE4B 426/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | CHRM3 445/4885PDE4A 719/4885PDE4B 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.